Jake Bauer

Jake Bauer is currently Chairman at Bridgebio Oncology Therapeutics, Inc. and Simcha Therapeutics, Inc. He is an Independent Director at Immunovant, Inc., Enliven Therapeutics, Inc., and Attralus, Inc. He serves as Director at Simcha Therapeutics Holding Co. LLC and Enliven Therapeutics, Inc. He is a Venture Partner at ARCH Venture Partners LLC, GSK Equity Investments Ltd., and SR One Capital Management LP.
Formerly, Mr. Bauer was Director at Phoenix Tissue Repair, Inc. from 2018 to 2022.
He was Independent Director at ARYA Sciences Acquisition Corp.
V from 2021 to 2023 and at ARYA Sciences Acquisition Corp.
II in 2020.
He was VP-Business Operations & Head-Development at Ablexis LLC from 2011 to 2014.
He served as Chief Business Officer at MyoKardia, Inc. from 2018 to 2020.
He worked as Consultant at Bristol Myers Squibb Co. from 2020 to 2021.
He was Management Consultant at Putnam Associates LLC from 2001 to 2005.
He was Principal at Zafgen, Inc., Global Blood Therapeutics, Inc., Royalty Pharma Cayman Partners LP, Endo Health Solutions, Inc., CytomX LLC, Agios Pharmaceuticals, Inc., and Third Rock Ventures LLC from 2007 to 2011.
Education includes an undergraduate degree from Duke University conferred in 2001 and an MBA from Harvard Business School conferred in 2007.